Biohaven Pharmaceutical Holding PE Ratio 2016-2022 | BHVN

Current and historical p/e ratio for Biohaven Pharmaceutical Holding (BHVN) from 2016 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Biohaven Pharmaceutical Holding PE ratio as of September 23, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Biohaven Pharmaceutical Holding PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-09-26 151.97 0.00
2022-06-30 145.71 $-14.82 0.00
2022-03-31 118.57 $-11.84 0.00
2021-12-31 137.81 $-13.08 0.00
2021-09-30 138.91 $-13.69 0.00
2021-06-30 97.08 $-14.33 0.00
2021-03-31 68.35 $-14.18 0.00
2020-12-31 85.71 $-13.04 0.00
2020-09-30 65.01 $-12.27 0.00
2020-06-30 73.11 $-11.04 0.00
2020-03-31 34.03 $-12.63 0.00
2019-12-31 54.44 $-10.97 0.00
2019-09-30 41.72 $-9.46 0.00
2019-06-30 43.79 $-8.95 0.00
2019-03-31 51.47 $-5.29 0.00
2018-12-31 36.98 $-6.20 0.00
2018-09-30 37.55 $-5.61 0.00
2018-06-30 39.52 $-5.27 0.00
2018-03-31 25.76 $-6.04 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.873B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00